The VEGF/DLL4 bispecific antibody (CTX-009/ES104) has successfully achieved its primary endpoint in a Phase 2/3 clinical trial for biliary tract cancer (BTC), showing potential as a new global stand...

We are proud to announce that Elpiscience will be hosting the prestigious International Symposium on Cell Engagers and Cancer Immunotherapy in Crowne Plaza, Suzhou, China on June 28-29, 2024.&nbs...

Shanghai, Suzhou, China April 3,2024 Elpiscience Biopharmaceuticals announces the Appointment of Jason Luke M.D., to its Scientific Advisory Board.   “We are excited to have Dr. Luke ...

Elpiscience Biopharma, Ltd.  and Astellas Pharma Inc. today announced a research collaboration and license agreement for novel bi-specific macrophage engagers, ES019 and another program.

Elpiscience Biopharmaceuticals presented studies for its innovative immunotherapeutic molecules at the SITC 2023 Annual Meeting. Check out the highlights.

Elpiscience Biopharmaceuticals today announced it will have three poster presentations at the SITC 2023 Annual Meeting taking place November 3-5, 2023, in San Diego.